반응 #2291136

ord-81ff9de2535f46e5aee9757f7bc38fb6

용매

반응 조건

상세 조건
See reaction.notes.procedure_details.

후처리

  1. 1
    농축concentrated to dryness
  2. 2
    기타The resulting residue was then purified by reverse phase chromatography (Biotage SP4
  3. 3
    workup.DISSOLUTIONThe resulting product was dissolved in minimal DCM (with MeOH to aid solubility)
  4. 4
    workup.ADDITIONadded to a stirred solution of 1M HCl in ether
  5. 5
    여과The resulting solid was filtered
  6. 6
    세척washed with ether
  7. 7
    기타dried

실험 절차

(R)-tert-Butyl 1-(5-chloro-3-propionamido-1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-3-yl(methyl)carbamate (0.180 g, 0.413 mmol) was placed in DCM (3 mL) at room temperature. TFA (1 mL) was then added, and the reaction was stirred at room temperature for 1 hour and concentrated to dryness. The resulting residue was then purified by reverse phase chromatography (Biotage SP4, C-18 12M+, 0-50% CH3CN/water). The resulting product was dissolved in minimal DCM (with MeOH to aid solubility) and added to a stirred solution of 1M HCl in ether. The resulting solid was filtered, washed with ether and dried to give (R)—N-(5-chloro-4-(3-(methylamino)piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionamide hydrochloride (0.150 g, 89% yield) as a solid. 1H NMR (400 MHz, D2O) δ 8.13 (s, 1H), 7.28 (s, 1H), 3.87-3.84 (m, 1H), 3.42-3.37 (m, 2H), 3.20-3.14 (m, 2H), 2.59 (s, 3H), 2.42-2.37 (q, 2H), 1.15-2.13 (m, 1H), 1.79-1.75 (m, 1H), 1.65-1.52 (m, 2H), 1.10-1.06 (t, 3H). LCMS (APCI+) m/z 336 (M+H)+.

출처

DOI: 10.6084/m9.figshare.5104873.v1특허: US09365568B2uspto-grants-2016_06